Serrapeptase - Uses, Side Effects, Warnings, and More

Serrapeptase – Uses, Side Effects, Warnings, and More

Serrapeptase – Uses, Side Effects, Warnings, and More

serrapeptase dangers,serrapeptase uses,signs serrapeptase is working,serrapeptase and cancer,serrapeptase side effects liver,serrapeptase benefits,does serrapeptase cause hair loss, serrapeptase dangers,serrapeptase uses,serrapeptase and cancer,serrapeptase benefits, serrapeptase side effects liver,signs serrapeptase is working

Overview

The silkworm is the source of the chemical known as serrapeptase. In both Japan and Europe, it is a widely prescribed medication (manufactured by Takeda Chemical Industries). In the United States, serrapeptase falls under the category of dietary supplement.

Serrapeptase is used for ailments such as back pain, osteoarthritis, and rheumatoid arthritis, as well as for conditions that are generally associated with pain and swelling (inflammation), despite the fact that there is not sufficient evidence to support these uses.

How does it operate?

The enzyme serrapeptase assists the body in the process of breaking down protein. It’s possible that this will assist reduce inflammation and mucus.

DO NOT MISS: Licorice – Uses, Side Effects, Warnings, and More

What Are the Benefits and Applications?

At this time, we do not have any information regarding the uses of SERRAPEPTASE.

Adverse Reactions

When used orally, Serrapeptase is considered to be POSSIBLY SAFE for adults when administered orally for a period of up to four weeks. There is not enough trustworthy information to determine whether or if using serrapeptase for a period of more than four weeks is safe.

Important Safety Instructions and Cautionary Notes

When used orally, Serrapeptase is considered to be POSSIBLY SAFE for adults when administered orally for a period of up to four weeks. There is not enough trustworthy information to determine whether or if using serrapeptase for a period of more than four weeks is safe. There is not enough trustworthy information available to determine whether or not using serrapeptase is safe when pregnant or breastfeeding. Pregnancy and breastfeeding: To be on the safe side, you should avoid using it.

Bleeding problems: Because serrapeptase has the potential to disrupt the clotting process in the blood, some researchers are concerned that it could make bleeding disorders even more severe. Before using serrapeptase, if you have a bleeding issue, it is important to consult with your primary care physician.

Serrapeptase may cause complications during surgical procedures by preventing normal blood clotting. There is a possibility that it could lead to an increase in bleeding both during and after the operation. At least two weeks before a scheduled operation, you should finish using serrapeptase.

What are the interactions?

Interaction that is Not Overbearing

Take precautions when using these two together.

Medications that prevent or inhibit the formation of blood clots, known as anticoagulants and antiplatelet medications, have interaction with SERRAPEPTASE.

It’s possible that serrapeptase will make it harder for blood to clot. Consequently, there is a possibility that the risk of bruising and bleeding will be increased while taking serrapeptase in conjunction with other drugs that also inhibit the coagulation process.

Aspirin, clopidogrel (Plavix), diclofenac (Voltaren, Cataflam, and other brands), ibuprofen (Advil, Motrin, and other brands), naproxen (Anaprox, Naprosyn, and other brands), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, warfarin (Coumadin), and other drugs are all examples of

Dosing

In the course of scientific inquiry, the following doses have been investigated:

BY WAY OF THE MOUTH: For the reduction of swelling on the inside of the cheek following sinus surgery: 10 milligrams of serrapeptase should be taken three times on the day before surgery, once in the evening after surgery, and then three times on a daily basis for the next five days after surgery.

Leave a Comment

Your email address will not be published. Required fields are marked *